{
    "clinical_study": {
        "@rank": "26703", 
        "arm_group": [
            {
                "arm_group_label": "Opioid treatment group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization."
            }, 
            {
                "arm_group_label": "Nausea-observational group", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients given ondansetron by ED provider decision or by triage nurse. This is an observational cohort only."
            }
        ], 
        "brief_summary": {
            "textblock": "This study examines how hepatic cytochrome CYP2D6 drug interactions affects the efficacy of\n      oxycodone, hydrocodone, and ondansetron in Emergency Department (ED) patients."
        }, 
        "brief_title": "Emergency Department (ED) Drug Interaction in Emergency Department Patients", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Drug Interactions", 
        "condition_browse": {
            "mesh_term": "Emergencies"
        }, 
        "detailed_description": {
            "textblock": "Patients with pain and/or nausea are enrolled in the Emergency Department (ED). They are\n      given either oxycodone, hydrocodone, or ondansetron at the discretion of the Emergency\n      Department (ED) provider or the triage nurse by triage protocol. Detailed prescription, over\n      the counter, herbal, supplement, and illicit drug ingestion histories are taken from the\n      patient or their health care proxy. Serial visual analogue scales are captured prior to\n      study drug administration then between 30 and 90 minutes following drug administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  self-reported pain or nausea identified by the initial nursing assessment\n\n        Exclusion Criteria:\n\n          -  unable to speak English,\n\n          -  < 18 y.o.,\n\n          -  previously diagnosed with chronic pain or cyclic vomiting"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "502", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859715", 
            "org_study_id": "11-1692"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Opioid treatment group", 
                    "Nausea-observational group"
                ], 
                "description": "Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug", 
                "other_name": "Oxycodone, oxycontin"
            }, 
            {
                "arm_group_label": [
                    "Opioid treatment group", 
                    "Nausea-observational group"
                ], 
                "description": "Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.", 
                "intervention_name": "Hydrocodone", 
                "intervention_type": "Drug", 
                "other_name": "Vicodin"
            }, 
            {
                "arm_group_label": "Nausea-observational group", 
                "description": "Subjects given ondansetron for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.", 
                "intervention_name": "Ondansetron", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrocodone", 
                "Oxycodone", 
                "Acetaminophen, hydrocodone drug combination", 
                "Ondansetron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug drug interaction", 
            "CYP2D6", 
            "opioid efficacy", 
            "pain", 
            "nausea"
        ], 
        "lastchanged_date": "May 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aurora", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80403"
                }, 
                "name": "University of Colorado"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Hepatic Cytochrome Drug Interactions in Emergency Department Patients", 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Andrew A Monte, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Clinically significant visual analogue scale (VAS) oxycodone, hydrocodone, or ondansetron. Clinically significant change defined as 13 mm change.", 
            "measure": "difference in clinically significant visual analogue scale (VAS) change between CYP2D6 users and non-users", 
            "safety_issue": "No", 
            "time_frame": "90 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Determine if there is a difference in ADEs between groups with and without CYP2D6 drug interactions.", 
            "measure": "Adverse drug events", 
            "safety_issue": "Yes", 
            "time_frame": "Duration of ED stay, <24 hours. (up to 24 hours)"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}